💊 药物 A-Z 🧬 靶点 🛠 工具 📚 指南
全部药物 药物分类 治疗领域 不良反应
指南 术语表 时间轴
药物比较 药物旅程 药物家族
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Simoctocog Alfa

CHEMBL2108319 Phase 4 已批准 Protein
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Simoctocog alfa is a recombinant B-domain deleted human coagulation factor VIII produced in human embryonic kidney cells, used for the prevention and treatment of bleeding episodes in patients with hemophilia A. As a B-domain deleted factor VIII, it retains full procoagulant activity while offering manufacturing advantages including human cell line production that may reduce immunogenicity. It is administered intravenously for on-demand bleeding treatment and prophylaxis.

作用机制

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

Simoctocog alfa is a recombinant B-domain deleted human coagulation factor VIII produced in human embryonic kidney cells, used for the prevention and treatment of bleeding episodes in patients with hemophilia A. As a B-domain deleted factor VIII, it retains full procoagulant activity while offering manufacturing advantages including human cell line production that may reduce immunogenicity. It is administered intravenously for on-demand bleeding treatment and prophylaxis.

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Yes, Simoctocog Alfa is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2108319. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.